In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy targeting cash-paying patients through telehealth partners, Merck enters an $838 million research collaboration with antibody discovery startup Infinimmune, and Eli Lilly agrees to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion to expand into sleep-wake disorder treatments.